In 2012, Whyte et al. (2012) presented the first report on bone-targeted enzyme-replacement therapy with recombinant human TNALP (Strensiq® (asfotase alfa), Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease, Boston, MA, USA) in infants and young children with life-threatening perinatal or infantile HPP. This evidence concerns the gene ALPL and hypophosphatasia.